ReviewCells2021
Harnessing CD8
Review in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 21 citations in OpenAlex.
- Predictive value of peripheral lymphocyte subsets in relation to opportunistic infections in people living with HIV/AIDS.BMC infectious diseases · 2026Article
- Liriodendron attenuates intestinal fibrosis and inflammation in mice with radiation proctopathy.Chinese medicine · 2025Article
- Immune cell contribution to vascular complications in diabetes.Frontiers in endocrinology · 2025Review
- Unraveling the Causal Links Between Immune Cells, Lipids, and Cardiovascular Diseases: Insights from Mendelian Randomization.Global heart · 2025Article
- The application of peripheral blood immune profiling in personalized treatment of locally advanced and advanced lung cancer: a nomogram approach.Frontiers in oncology · 2025Article
- Targeting TNFR2 for cancer immunotherapy: recent advances and future directions.Journal of translational medicine · 2024Review
- Heterogeneity of lymphocyte subsets in predicting immune checkpoint inhibitor treatment response in advanced lung cancer: an analysis across different pathological types, therapeutic drugs, and age groups.Translational lung cancer research · 2024Article
- D-mannose reduces oxidative stress, inhibits inflammation, and increases treg cell proportions in mice with ulcerative colitis.Frontiers in pharmacology · 2024Article
- CD8Journal of clinical medicine · 2023Article
- Peripheral immune markers and amyotrophic lateral sclerosis: a Mendelian randomization study.Frontiers in neuroscience · 2023Article
- CD8International journal of molecular sciences · 2022Review
- CD8+ T-Cells in Juvenile-Onset SLE: From Pathogenesis to Comorbidities.Frontiers in medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 2 countries.
Funding
Abstract
T regulatory cell therapy presents a novel therapeutic strategy for patients with autoimmune diseases or who are undergoing transplantation. At present, the CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.